MCP
DMIIU

Maso Capital Partners’s Drugs Made In America Acquisition II Corp Unit DMIIU Stock Holding History

Maso Capital Partners’s Portfolio DMIIU Stock Details DMIIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$995K Buy
+100,000
New +$997K 1.63% 12

Other funds holding DMIIU

MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Maso Capital Partners's DMIIU Position: Q3 2025 in Review

Maso Capital Partners opened a new position in Drugs Made In America Acquisition II Corp Unit (DMIIU) in Q3 2025: 100,000 shares worth $995K. The stake represents 1.63% of the portfolio and ranks #12 among its holdings.

75 funds tracked by Wall St. Rank hold DMIIU as of Q3 2025.

  • Maso Capital Partners held 100,000 shares of Drugs Made In America Acquisition II Corp Unit worth $995K as of Q3 2025.
  • Drugs Made In America Acquisition II Corp Unit was a new Maso Capital Partners position in Q3 2025.
  • Drugs Made In America Acquisition II Corp Unit made up 1.63% of Maso Capital Partners's portfolio in Q3 2025, its #12 holding.
  • 75 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp Unit as of Q3 2025.

Based on Maso Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.